BioCapital
Filter News
Found 43,537 articles
-
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74
4/8/2024
NextCure, Inc. (Nasdaq: NXTC) today announced the presentation of new preclinical data on LNCB74, a B7-H4-targeting antibody drug conjugate (ADC) developed in partnership with LigaChem Biosciences (LCB), formerly LegoChem Biosciences, (KOSDAQ: 141080), at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
4/6/2024
AstraZeneca and Daiichi Sankyo's ENHERTU® has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
-
Breakthrough Designated CorVista® System with Pulmonary Hypertension Add-On Cleared by FDA; Enabling Advanced Cardiovascular Testing at Point-of-Care
4/5/2024
Analytics for Life, Inc. and CorVista Health Inc. announced the FDA clearance of the CorVista System with Pulmonary Hypertension (PH) Add-On Module.
-
FDA Roundup: April 5, 2024
4/5/2024
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
-
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
4/5/2024
Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival in patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy compared to placebo after cCRT.
-
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
4/5/2024
I-Mab announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.
-
NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024
4/5/2024
NiKang Therapeutics Inc. announced today the unveiling of NKT3447 at the American Association for Cancer Research (AACR) Annual Meeting 2024. NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDK.
-
Sebia Receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices
4/5/2024
Sebia announced that it has received 510 clearance from the U.S. Food and Drug Administration for CAPILLARYS 3 DBS devices. Our solution is intended for the detection of normal hemoglobins and abnormal hemoglobins in blood from human newborn collected on filter paper.
-
Precision Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting on April 8th, 2024
4/5/2024
Precision Biologics, Inc. reports its lead monoclonal antibody, NEO-201, targets circulating human naïve regulatory T cells (Tregs) in both healthy donors and cancer patients.
-
Charles River to Perform Plasmid Production for Ship of Theseus
4/4/2024
Charles River Laboratories International, Inc. and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox family biologics, announced a Good Manufacturing Practice- plasmid DNA contract development and manufacturing organization agreement.
-
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
4/4/2024
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.
-
Cartesian Therapeutics Announces New Employment Inducement Grants
4/4/2024
Cartesian Therapeutics, Inc. today announced the granting of inducement awards to four new employees. On April 1, 2024, the Company issued to each of these employees an option to purchase shares of the Company’s common stock with an exercise price of $0.5601, the closing trading price of the Company’s common stock.
-
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
4/4/2024
Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), has signed a collaboration agreement with Lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets.
-
EILEAN THERAPEUTICS RECEIVES CLEARANCE TO INITIATE R/R AML TRIAL WITH LOMONITINIB, A SELECTIVE PAN-FLT3/IRAK4 INHIBITOR
4/4/2024
Eilean Therapeutics LLC is pleased to announce the clearance from the Human Research Ethics Committee in Australia for lomonitinib (ZE46-0134) allowing the company to proceed with a Phase I clinical trial in relapsed/refractory (R/R) AML.
-
Anivive to Present Groundbreaking Research on First Systemic Antifungal Vaccine at World Vaccine Congress
4/4/2024
Anivive Lifesciences, is set to unveil groundbreaking research at the upcoming World Vaccine Congress , where they will present findings on the development of the world's first systemic antifungal vaccine – A solution for both ends of the leash.
-
QuantalX Secures Spot in FDA's Prestigious Total Life Cycle Advisory Program (TAP)
4/4/2024
QuantalX Neuroscience, a pioneering healthcare company dedicated to early detection of brain disorders using the Delphi-MD medical device, announced its selection to participate in the highly prestigious Total Life Cycle Advisory Program initiated by the U.S. Food and Drug Administration.
-
Immunocore to present at upcoming April 2024 investor conferences
4/4/2024
Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, announced that management will participate in the following investor conferences in April.
-
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4/4/2024
Cartesian Therapeutics, Inc. today announced that its management expects to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:00 p.m. ET.
-
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
4/3/2024
60 Degrees Pharmaceuticals, Inc. announced today that the Company will sponsor a pilot study of tafenoquine , the active molecule in its U.S. Food and Drug Administration (FDA)-approved human malaria prevention medication, ARAKODA®, for the treatment of babesiosis in dogs.
-
FDA Approves New Antibiotic for Three Different Uses
4/3/2024
Today, the U.S. Food and Drug Administration approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis; adults with acute bacterial skin and skin structure infections (ABSSSI); and adult and pediatric patients three months to less than 18 years old with community-acquired bacterial pneumonia (CABP).